Restriction of influenza infection by cyclin D3
Ying Fan,Chris Ka-Pun Mok,Michael Chi Wai Chan,Yang Zhang,Béatrice Nal,François Kien,Roberto Bruzzone,Sumana Sanyal
2017-01-01
Abstract:To identify new host factors that modulate the replication of influenza A virus, we performed a yeast two-hybrid screen using the cytoplasmic tail of matrix protein 2 from the highly pathogenic H5N1 strain. The screen revealed a high-score interaction with cyclin D3, a key regulator of cell cycle early G1 phase. M2–cyclin D3 interaction was validated through GST pull-down and recapitulated in influenza A/WSN/33-infected cells. Knockdown of Ccnd3 by small interfering RNA significantly enhanced virus progeny titers in cell culture supernatants. Interestingly, the increase in virus production was due to cyclin D3 deficiency per se, and not merely a consequence of cell cycle deregulation. A combined knockdown of Ccnd3 and Rb1, which rescued cell cycle progression into the S phase, failed to normalize virus production. Infection by IAV triggered redistribution of cyclin D3 from the nucleus to the cytoplasm followed by its proteasomal degradation. When over-expressed in HEK 293T cells cyclin D3 impaired binding of M2 with M1, which is essential for proper assembly of progeny virions, lending further support to its role as a putative restriction factor. Our study describes the identification and characterization of cyclin D3 as a novel interactor of influenza A virus M2 protein. We hypothesize that competitive inhibition Restriction of influenza infection by cyclin D3 2 of M1–M2 interaction by cyclin D3 impairs infectious virion formation and results in attenuated virus production. In addition, we provide mechanistic insights into the dynamic interplay of influenza virus with the host cell cycle machinery during infection. INTRODUCTION The threat of influenza infection is felt globally as the disease leads to an estimated 3 to 5 million cases of severe illness, and about 250,000 to 500,000 deaths each year (1). Although the strategy of antagonizing influenza infection through vaccination has been partially successful, the necessity for effective antiviral agents is underscored by the toxic side effects of currently available drugs and the emergence of drug-resistant variants (2-4). Influenza viruses, like any other viruses, are obligate intracellular pathogens that exploit the host cellular machinery to replicate. The identification of cellular mechanisms required for virus life cycle not only sheds light on its trafficking characteristics but also provides strategies for interfering with host factors as an alternative approach to inhibit viral infection. Elucidating host-pathogen interactions as an unbiased approach to gain insights into disease pathogenesis has received ample attention. Various functional assay systems have been used for screening host factors involved in the influenza virus replication cycle thus far. From RNA interference (RNAi)-based genome-wide screening strategies in Drosophila (5) and mammalian systems (6-9) to other approaches including proteomics (10,11), yeast two-hybrid (Y2H) analyses (7,12), as well as microarrays (7,13-15), extensive information has been acquired. Multiple cellular networks have been implicated in influenza virus replication either through direct protein-protein interactions (10,16) or signaling pathways (17). Although these strategies unveiled hundreds of genes important for the virus life cycle, their functional relevance and molecular mechanisms are still poorly understood. Amongst others, effort has been invested to dissect how the cellular interactors of viral ribonucleoprotein (vRNP) complexes regulate the replication and transcription of influenza virus (18). Host interactors of the non-structural protein 1 (NS1), a multifunctional protein modulating several aspects of the virus replication cycle with a major role in inhibiting interferon mediated immune response, have also been extensively studied (16). However, little attention has been drawn to identify cellular factors associated with the viral matrix protein 2 (M2). We reasoned that the integral membrane proteins of the viral envelope would interact with cellular factors at various stages: endosomal fusion and release of the genetic material during entry, transport from endoplasmic reticulum (ER) to the plasma membrane and during assembly and budding of nascent virions. M2 is a minor protein of the viral envelope that forms a homotetramer in its native state (19,20). Interestingly, M2 possesses the longest C-terminal tail among the three viral envelope proteins, namely hemagglutinin (HA), neuraminidase (NA), and M2. It is an ion channel that was initially discovered as the target of the anti-viral drug amantadine and facilitates diffusion of protons to the interior of the endosomally entrapped virus (21). Low pH induces a conformational change in HA and subsequently triggers fusion with the endosomal membrane during virus entry (22). M2 is a 97-residue single-pass membrane protein that displays Restriction of influenza infection by cyclin D3 3 considerable pleiotropism. It determines the filamentous morphology of some viral strains through binding to cholesterol (23-25). The cytoplasmic tail (CT) of M2 interacts with M1 at the site of virus budding for efficient packaging of virus particles (26,27). Rossman et al reported a role of M2-CT in mediating cholesterol-dependent alteration in membrane curvature at the neck of budding virions, leading to host ESCRT pathway-independent membrane scission (28). Altogether, these studies provide evidence that influenza M2, especially the CT domain, plays a critical role in multiple steps of the virus life cycle. Hence, the identification of cellular interactors of M2 would provide mechanistic insights into influenza pathogenesis and possibilities for development of novel strategies to interfere with multiple steps of the infection process. By using M2-CT as bait, we screened a human placenta cDNA library to identify host proteins that either facilitate or restrict viral infection. Cyclin D3, a key regulator of cell cycle G0/G1 phase progression, was uncovered as a novel host factor interacting with M2-CT. The physical interaction between M2 and cyclin D3 was confirmed in virus-infected cells. IAV infection resulted in host cell cycle arrest in the G0/G1 phase, which was accompanied by cyclin D3 relocalization and degradation. Using a combination of small interfering RNA (siRNA) mediated genetic analyses we further showed that cyclin D3 restricts IAV production, independent of its role in cell cycle. The restriction of cyclin D3 on IAV life cycle did not impair viral protein synthesis, but interfered with M1–M2 binding, which may result in defective assembly and release of progeny virions. The role of cyclin D3 in the context of influenza infection has not been described previously. More interestingly, our results suggest a novel function of cyclin D3 that is beyond its classical function in cell cycle regulation. RESULT Identification of cyclin D3 as M2-CT binding protein The IAV M2 ion channel protein is a multifunctional protein with a highly conserved sequence among influenza A virus isolates that approaches 95% identity in some regions (29,30). Among the three viral envelope proteins, M2 possesses the longest CT with a high probability of interactions with the cellular machinery at various steps of the virus life cycle. These include fusion, intracellular trafficking through the secretory pathway (31), as well as virus assembly and budding at the plasma membrane (24,32). It is of considerable interest to identify intracellular interactors of M2-CT, not only to elucidate cellular components that are exploited by influenza but also to understand host defenses involved in restricting virus life cycle. To this end, a random-primed cDNA library from human placenta was screened by Y2H using the IAV M2-CT as bait (Figure 1A). The screening revealed human cyclin D3 (GenBank accession no. NM_001760.2) as one of the most prominent interactors of M2-CT as summarized in Table 1. Sequence alignment of the positive clones pointed to amino acid residues 138 to 251 as the minimal interacting domain for M2-CT (Figure 1B). The M2-binding domain on cyclin D3 is largely outside of its cyclin box, which is responsible for binding to and activation of cyclin dependent kinases (33,34) and also the region in which the greatest homology occurs among the D-type cyclins (35). This finding, together with the Restriction of influenza infection by cyclin D3 4 absence of other cyclins among positive clones, suggests a certain degree of specificity of the interaction, which was tested in the next series of experiments. Cyclin D forms a complex with and functions as a regulatory subunit of cyclin dependent kinase (CDK) 4 and 6, whose activity is required in the cell cycle early G1 phase (36). There are three early G1 phase D-type cyclins (D1, D2 and D3), which are functionally related with tissue-specific expression profiles (37-43). Our results from Y2H screening indicate that only cyclin D3 but not the other two D-type cyclins interact with M2-CT. We first checked the specificity of this interaction in human A549 lung epithelial cells. GST–M2-CT fusion protein was purified and incubated with wild-type cell lysate to pull-down endogenous D-type cyclins. Cyclin D3 bound specifically to GST–M2-CT and not to either GST or beads (Figure 1C). Altogether, these results confirm that cyclin D3 binds to the IAV M2-CT. To examine the intracellular association of M2-CT with cyclin D3 during the IAV life cycle, co-immunoprecipitation experiments were performed from virus-infected cells. HEK 293T cells were transiently transfected with a plasmid encoding flag-tagged cyclin D3 (cyclin D3-Flag) and infected with influenza A/WSN/33 virus. Cell lysates were immunoprecipitated with anti-flag antibody and immunoblotted with anti-M2 antibody. As shown in Figure 1D (lane 1), M2 was found to co-purify with cyclin D3, demonstrating their physical interaction during virus infection, either directly or through a common i